SCHEMBL16136752

SCHEMBL16136752

CCc1c(C(=O)NN2CCS(=O)(=O)CC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Br)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 11/20 0.82
CNR2 P34972 6/20 0.82
KCNH2 Q12809 2/20 0.58
ABCC4 O15439 1/20 0.56
MLNR O43193 1/20 0.56
ABCB11 O95342 1/20 0.56
CHRM2 P08172 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
CYP2C9 P11712 1/20 0.56
ADRA2B P18089 1/20 0.56
ADRA2C P18825 1/20 0.56
DRD1 P21728 1/20 0.56
TBXA2R P21731 1/20 0.56
SLC6A2 P23975 1/20 0.56
HRH2 P25021 1/20 0.56
HTR2A P28223 1/20 0.56
AGTR1 P30556 1/20 0.56
CCKAR P32238 1/20 0.56
CCKBR P32239 1/20 0.56
MC4R P32245 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16136678 0.95 CNR1 (0.73) CNR1CNR2KCNH2ABCC4MLNR
SCHEMBL16136753 0.93 CNR1 (0.82) CNR1CNR2KCNH2ABCC4MLNR
SCHEMBL16136681 0.92 CNR1 (0.70) CNR1CNR2KCNH2ABCC4MLNR
SCHEMBL16136664 0.92 CNR1 (0.70) CNR1CNR2KCNH2ABCC4MLNR
Surinabant SCHEMBL675894 0.91 CNR1 (1.00) CNR1CNR2KCNH2ABCC4MLNR
Surinabant SCHEMBL30953789 0.91 CNR1 (1.00) CNR1CNR2KCNH2ABCC4MLNR
SCHEMBL16136671 0.89 CNR1 (0.82) CNR1CNR2KCNH2ABCC4MLNR
SCHEMBL30961555 0.89 CNR1 (0.82) CNR1CNR2KCNH2ABCC4MLNR
SCHEMBL6162630 0.88 CNR1 (0.82) CNR1CNR2KCNH2ABCC4MLNR
SCHEMBL16136754 0.88 CNR1 (0.64) CNR1CNR2KCNH2ABCC4MLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853205-B2 Heteropyrrole analogs acting on cannabinoid receptors UNIVERSITY OF CONNECTICUT (US) 2014-10-07 US claimed
US-20230234928-A1 Novel Compounds for Treating Fibrosis and Inflammatory Conditions MAKSCIENTIFIC, LLC 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234928-A1 Novel Compounds for Treating Fibrosis and Inflammatory Conditions CNR2, CNR1, GPR174 CNR1 2/4885CNR2 1/4885KCNH2 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.